ВАН Вэй (US),БАНС Вирджиния (US),ТРИВЕДИ Харш М. (US),СЮЙ Тао (US)
申请号：
RU2012130956/14
公开号：
RU2012130956A
申请日:
2010.12.21
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of treating a condition associated with abnormal expression of MMP-13, comprising administering to a subject a therapeutically effective amount of 4-acetamidophenyl 2-isopropyl-5-methylcyclohexylcarbonate. The method according to claim 1, further comprising administering to the subject a therapeutically effective amount of one or more of the following substances: non-dialyzable material from cranberry extract, acetyl-keto-β-boswellic acid, resveratrol and 2-isopropyl-5-methylcyclohexyl 2-hydroxyphenylcarbamate. The method of claim 2, comprising administering to the subject a non-dialyzable material from cranberry extract. The method according to claim 2, comprising administering to the subject acetyl-keto- (B-boswellic acid. 5. The method according to claim 2, comprising administering resveratrol to the subject. 6. The method according to claim 2, comprising administering 2-isopropyl-5-methylcyclohexyl to the subject 2-hydroxyphenylcarbamate 7. The method according to any one of claims 1 to 6, wherein the condition associated with abnormal expression of MMP-13 is selected from the group consisting of destruction of the extracellular matrix, loss of fixation of one or more teeth, tooth loss, tooth mobility, education pockets, bone loss, and combinations of two or more of these 8. A composition comprising a therapeutically effective amount of an MMP-13 inhibitor and an orally acceptable carrier, wherein the MMP-13 inhibitor is 4-acetamidophenyl 2-isopropyl-5-methylcyclohexyl carbonate 9. The composition of claim 8, further comprising an MMP inhibitor. -13, selected from the group consisting of non-dialyzable material of cranberry extract, acetyl-keto-β-boswellic acid, resveratrol, 2-isopropyl-5-methylcyclohexyl 2-hydroxyphenylcarbamate and a combination thereof�1. Способ лечения состояния, связанного с аномальной экспрессией ММП-13, включающий введение субъекту терапевтически эффективного количества 4-ацетамидофенил 2-изопропил-5-метилциклогексилкарбоната.
